Drugs / Telcagepant
Telcagepant
also known as
MK-0974 · telcagepant potassium · Telcagepant potassium ethanol · Telcagepant potassium salt monoethanolate
Small molecule targets CALCRL via inhibition
Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials · 1 met primary | ||||||
| Phase 1 | NCT01315847 | Jan 2010 → Jul 2011 | migraine disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01294709 | Feb 2008 → Feb 2009 | coronary artery disorder | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 1 | NCT00701389 | Nov 2007 → Apr 2008 | migraine disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT00758836 | Dec 2008 → Aug 2009 | migraine disorder | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 2 | NCT00797667 | Nov 2008 → May 2009 | migraine disorder | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00246337 | Nov 2005 → May 2006 | migraine disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT01125774 | Jun 2010 → Apr 2011 | migraine disorder | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 35 trials · 3 met primary · 1 missed | ||||||
| Phase 3 | NCT00483704 | Aug 2008 → Mar 2009 | migraine disorder | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00662818 | Mar 2008 → Sep 2009 | heart disorder, migraine disorder, peripheral vascular disease, transient ischemic attack | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 3 | NCT00432237 | Mar → Dec 2007 | migraine disorder | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00443209 | Feb 2007 → Jan 2009 | migraine disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00442936 | Feb → Oct 2007 | migraine disorder | Merck Sharp & Dohme LLC | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01209741 Comparator | Oct → Nov 2007 | migraine disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | telcagepant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01209741 ↗ |
| Known as | MK-0974 | “The purpose of the study is to assess the safety and efficacy of telcagepant (MK-0974) in acute treatment of multiple migraine attacks with or without aura.” NCT00483704 ↗6“Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura (MK-0974-011)” NCT00442936 ↗ “Telcagepant (MK-0974) Long-Term Safety Study in Adult Participants With Acute Migraine (MK-0974-012)” NCT00443209 ↗ “Telcagepant (MK-0974) (300 mg soft gel capsules or 280 mg tablets)” NCT00662818 ↗ “CGRP-receptor antagonist telcagepant (MK-0974)” PMID 23798725 ↗ Jun 2013 |
| Known as | telcagepant potassium | “Drug: telcagepant potassium” NCT01209741 ↗1“Drug: telcagepant potassium” NCT00701389 ↗ |
| Known as | Telcagepant potassium ethanol | ChEMBL registry synonym — accepted as the source's own label CHEMBL236593 ↗ |
| Known as | Telcagepant potassium salt monoethanolate | ChEMBL registry synonym — accepted as the source's own label CHEMBL236593 ↗ |
| Action | Inhibit | “Calcitonin gene-related peptide type 1 receptor antagonist” CHEMBL236593 ↗1“the first orally bioavailable CGRP receptor antagonist” PMID 19770473 ↗ Sep 2009 |
| Modality | Small molecule | — CHEMBL236593 ↗ |
| Route | Oral | “MK0974 25 mg; one orally-administered dose” NCT00246337 ↗ |
| Target | CALCRL | “Calcitonin gene-related peptide type 1 receptor antagonist” CHEMBL236593 ↗ |